Gut Dysbiosis and Neurodegeneration: Current Evidence and Future Directions
Gut dysbiosis is increasingly associated with neurodegenerative diseases through the gut–brain axis. Altered gut microbiota may influence neuroinflammation, intestinal and blood–brain barrier integrity, oxidative stress, protein aggregation, and neurotransmitter signaling through microbial metabolites. This review summarizes the current evidence linking gut dysbiosis with Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. It also discusses experimental models, microbiome-targeted therapies, multi-omics approaches, and artificial intelligence in microbiome research. Emerging strategies include dietary interventions, probiotics, prebiotics, postbiotics, fecal microbiota transplantation, phage therapy, precision microbiome therapy, and microbiome engineering. Despite promising findings, variability between individuals, lack of standardized methods, limited clinical evidence, and uncertainty regarding causality remain major challenges. Future research should emphasize standardized, longitudinal, and personalized approaches to establish the therapeutic potential of microbiome modulation in neurodegenerative diseases.
Authors
- Pooja Balkrishna Rasal (ORCID: https://orcid.org/0009-0003-3138-7340)
- Amol Uttamrao Gayke
- Vikas S. Shinde
- Diksha Devkate
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5281/zenodo.24300200
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00